Corporate Therapeutic Symposia

These company-based information sessions will provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

**Sunday, June 19, 2016**

**Cynapsus**

13:15-14:15

Location: Hall 7.2a Helsinki 1, Level 2

**From OFF to ON – Treating Levodopa-Induced OFF Periods**

Chairs: C. Warren Olanow
New York, NY, USA
Fabrizio Stocchi
Rome, Italy

Speakers: Anthony Schapira
London, United Kingdom
Karl Kieburtz
New York, NY, USA
C. Warren Olanow
New York, NY, USA

**GE Healthcare**

13:15-14:15

Location: Hall 7.2a Helsinki 1, Level 2

**A Debate on Appropriate Clinical Scenarios for DaT SPECT Imaging**

Chair: Stuart Isaacson
Boca Raton, FL, USA

Speakers: Britt Mollenhauer
Kassel, Germany
Angelo Antonini
Padua, Italy
Hubert Fernandez
Cleveland, OH, USA

**Monday, June 20, 2016**

**Adamas**

14:00-15:00

Location: Hall 7.2b Budapest, Level 2

**Levodopa Induced Dyskenisias: Assessment, Management, and Potential Treatments**

Chair: Rajesh Pahwa
Kansas City, MO, USA

Introduction and Program Goals; LID Overview: Risk Factors, Epidemiology, Terminology, and Current Management Strategies

Rajesh Pahwa
Kansas City, MO, USA

LID Burden: How Does It Impact the Patient and Caregiver?

Caroline Tanner
Sunnyvale, CA, USA

Dyskinesia Assessment in Clinical Trials: The UDysRS and Patient Home Diaries

Robert Hauser
Tampa, FL, USA

**Zambon**

14:00-15:00

Location: Hall A1, Level 1

**Safinamide – A Dual Effect to Improve the Management of Motor and Non-Motor Symptoms in Parkinson’s Disease**

Chairs: Wolfgang Jost
Stuttgart, Germany
C. Warren Olanow
New York, NY, USA

Dual Dopaminergic/Glutamatergic Modulation in Parkinson’s Disease

Michele Morari
Ferrara, Italy

Safinamide – A Unique Treatment Targeting Both Dopaminergic and Non-Dopaminergic Systems

Paulo Barone
Naples, Italy

Panel Discussion
### Britannia

**Monday, June 20, 2016, cont.**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-15:00</td>
<td><strong>How Can We Enhance Patient Outcomes With Current Therapies? Practical Approaches to Treatment Optimization in Parkinson’s Disease</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Claudia Trenkwalder&lt;br&gt;Kassel, Germany</td>
</tr>
<tr>
<td></td>
<td>Optimizing ON Time in Early Parkinson’s Disease&lt;br&gt;Stuart Issacson&lt;br&gt;Boca Raton, FL, USA</td>
</tr>
<tr>
<td></td>
<td>The Importance of Patient Selection and Monitoring with Continuous Dopaminergic Therapy&lt;br&gt;Georg Ebersbach&lt;br&gt;Beelitz-Heilstatten, Germany</td>
</tr>
</tbody>
</table>

### AbbVie

**Tuesday, June 21, 2016, cont.**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-15:00</td>
<td><strong>Empowering Patients for Clinical Decision-Making in Advanced Parkinson’s Disease</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Werner Poewe&lt;br&gt;Innsbruck, Austria</td>
</tr>
<tr>
<td></td>
<td>Considering Timing of Device-Aided Therapies - Having Patients’ Quality of Life in Mind&lt;br&gt;Angelo Antonini&lt;br&gt;Venice, Italy</td>
</tr>
<tr>
<td></td>
<td>The Spectrum of Patients for Device-Aided Therapies - Clinical Data and Practical Considerations&lt;br&gt;K. Ray Chaudhuri&lt;br&gt;London, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>When and How to Educate Patients on Device-Aided Therapies - The Art of Making Informed Decisions&lt;br&gt;Alexander Storch&lt;br&gt;Rostock, Germany</td>
</tr>
</tbody>
</table>

### Ipsen

**Tuesday, June 21, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-15:00</td>
<td><strong>Cervical Dystonia Management with BoNT-A: Towards an Optimized Approach</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> David M. Simpson&lt;br&gt;New York, NY, USA</td>
</tr>
<tr>
<td></td>
<td>American Academy of Neurology Evidence Based Guidelines 2016 Update&lt;br&gt;David M. Simpson&lt;br&gt;New York, NY, USA</td>
</tr>
<tr>
<td></td>
<td>New Approaches to Differentiate and Treat Cervical Dystonia&lt;br&gt;Wolfgang Jost&lt;br&gt;Freiburg, Germany</td>
</tr>
<tr>
<td></td>
<td>Simplifying Injection Parameters for Botulinum Toxin in Cervical Dystonia&lt;br&gt;Marion Simonetta-Moreau&lt;br&gt;Toulouse, France</td>
</tr>
</tbody>
</table>

### ACADIA Pharmaceuticals

**Tuesday, June 21, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-15:00</td>
<td><strong>Treating the Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Daniel E. Kremens&lt;br&gt;Philadelphia, PA, USA</td>
</tr>
<tr>
<td></td>
<td>Rajesh Pahwa, MD&lt;br&gt;Kansas City, MO, USA</td>
</tr>
<tr>
<td></td>
<td>Due to the German Medicinal Products Act, attendance to this session is limited to delegates from the United States.</td>
</tr>
</tbody>
</table>
Corporate Therapeutic Symposia

Wednesday, June 22, 2016

**Bial**

13:30-14:30

Location: Hall 7.2b Budapest, Level 2

*Are We Fulfilling the Needs of Patients with Motor Fluctuations? The Role of COMT Inhibition*

Chair: Joaquim Ferreira
Lisbon, Portugal

Levodopa Motor Fluctuations and Current Treatment Strategies
Eduardo Tolosa
Barcelona, Spain

COMT Inhibition: Strengths and Weaknesses
Fabrizio Stocchi
Rome, Italy

Developments in COMT Inhibitors
Olivier Rascol
Toulouse, France

**Medtronic**

13:30-14:30

Location: Hall A1, Level 1

*Who Wants to be a DBS Master – Three DBS Experts Sharing Their Knowledge From Diagnosis to Follow Up Through a Quiz Show That Asks the Audience for Help*

Chair/Players: Bastiaan Bloem
Nijmegen, Netherlands
Lars Timmermann
Cologne, Germany
Stephan Chabardes
Grenoble, France

**Acorda Therapeutics**

13:30-14:30

Location: Hall A8, Level 1

*The Many Faces of OFF*

Chair: Matthew Stern
Philadelphia, PA, USA

The Many Faces of OFF
Anthony Lang
Toronto, ON, Canada

Primary Causes of Motor Fluctuations in PD
Peter LeWitt
Detroit, MI, USA

Emerging Levodopa Strategies to Address Motor Fluctuations
Robert Hauser
Tampa, FL, USA

**Thursday, June 23, 2016**

**Teva Pharmaceuticals**

13:30-14:30

Location: Hall A1, Level 1

*Emerging Therapies and Technologies in Movement Disorders*

Chair: Bernhard Landwehrmeyer
Ulm, Germany

Digital Health Technology
Ralf Reilmann
Münster, Germany

Dueteration Technology: SD-809 in Tourette’s Syndrome
Joseph Jankovic
Houston, Texas

Dueteration Technology: SD-809 in Tardive Dyskinesia
Hubert Fernandez
Cleveland, OH, USA